Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PharmenaWAR:PHR -1.27%55 Days Inventory is 875.87 as of Mar. 2026, which is 190% above its 10-year median of 301.57. GuruFocus rates WAR:PHR with a GF Score™ of 55/100 and a GF Value™ of zł5.71 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 638 Biotechnology companies, Pharmena ranks worse than 91.38% on this metric.
Days Inventory is also known as Days Sales of Inventory (DSI). Pharmena's Average Total Inventories for the
three
months ended in Mar. 2026 was zł0.68 Mil. Pharmena's Cost of Goods Sold for the
three
months ended in Mar. 2026 was zł0.07 Mil.
Hence, Pharmena's Days Inventory for the
three
months ended in Mar. 2026 was 875.87.
The historical rank and industry rank for Pharmena's Days Inventory or its related term are showing as below:
WAR:PHR'
s Days Inventory Range Over the Past 10 Years
Min: 168.59 Med: 301.57 Max: 2956.5
Current: 1011.79
During the past 13 years, Pharmena's highest Days Inventory was 2956.50. The lowest was 168.59. And the median was 301.57.
WAR:PHR's Days Inventory is ranked worse than 91.38% of 638
companies
in the Biotechnology industry
Industry Median: 183.195
vs WAR:PHR: 1011.79
Pharmena's Days Inventory
increased
from Mar. 2025 (659.08) to Mar. 2026 (875.87).
It might indicate that Pharmena's sales slowed down.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Pharmena's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.10.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Pharmena's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 1.62.
Pharmena (WAR:PHR) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Pharmena's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Pharmena's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Pharmena Days Inventory Related Terms
Pharmena Days Inventory Historical Data
* Premium members only.
The historical data trend for Pharmena's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:PHR vs VRTX, REGN, ALNY: Days Inventory Comparison
For the Biotechnology subindustry, Pharmena's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharmena Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharmena's Days Inventory distribution charts can be found below:
* The bar in red indicates where Pharmena's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharmena (WAR:PHR) has a Days Inventory of 875.87 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Pharmena and its competitors. This is 190% above median its historical median of 301.57. Over the past decade, Pharmena's Days Inventory has ranged from 168.59 to 2,956.50. According to the industry distribution chart, Pharmena ranks #583 out of 638 companies in the Biotechnology industry, placing it in the top 91.4%.
Is Pharmena's Days Inventory too high?
Pharmena's current Days Inventory of 875.87 is 190% above median its 10-year median of 301.57. Over the past 10 years, this metric has ranged from a low of 168.59 to a high of 2,956.50. The Biotechnology industry median Days Inventory is 183.20. Pharmena's value of 875.87 is 378.1% above this industry median. Based on the distribution chart, Pharmena ranks #583 out of 638 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Pharmena has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Pharmena's Days Inventory compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharmena ranks #583 out of 638 companies for Days Inventory. This places Pharmena in the lower half of its industry. The industry median Days Inventory is 183.20. Pharmena's value of 875.87 is 378.1% above this benchmark. Historically, Pharmena's own Days Inventory has ranged from 168.59 to 2,956.50 over the past decade. While the company's 10-year median is 301.57 vs. the industry median of 183.20, Pharmena has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.20, based on 638 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharmena's current Days Inventory of 875.87 is 378.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Pharmena and its competitors. For the Biotechnology industry, the median Days Inventory is 183.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharmena's current Days Inventory is 875.87, which is 190% above median its own 10-year median of 301.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmena stock overvalued right now?
Based on GuruFocus' analysis, Pharmena (WAR:PHR) is currently considered Possible Value Trap. The stock's GF Value™ is zł5.71, compared to a current price of zł3.11 — trading 45.5% below its estimated fair value. The current Days Inventory is 875.87, which is 190% above median its 10-year median of 301.57 and 378.1% above the Biotechnology industry median of 183.20. Pharmena's overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Pharmena (WAR:PHR), the current Days Inventory is 875.87 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharmena (WAR:PHR) Overvalued in 2026?
Based on GuruFocus' analysis, Pharmena stock appears to be undervalued.
The current stock price of zł3.11 is trading 45.5% below its estimated GF Value™ of zł5.71.
GuruFocus considers Pharmena to be Possible Value Trap.
Key valuation signals for WAR:PHR:
Days Inventory: 875.87 (190% above median its 10-year median of 301.57)
GF Value™: zł5.71 vs. price of zł3.11 (45.5% below fair value)
Industry Position: 378.1% above the Biotechnology median (#583 of 638)
No single metric tells the full story. See the WAR:PHR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharmena SA produces cosmeceuticals and pharmaceuticals. The company's activity focuses on three areas such as research in the USA and Canada on the application of selected pyridinium salts in medicine in order to develop an anti-atherosclerosis drug on a global scale, Production and sales of innovative patented dermocosmetics and introduction into the market of an innovative dietary supplement for atherosclerosis prophylaxis. Its products include Menavitin, Dermena, Allerco and Thermi.
55GF Score
Get the complete analysis for WAR:PHR
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:PHR has been successfully added to your 
